News

Press Releases

September 19, 2019
Neoleukin Therapeutics Announces Additions to Management Team

September 5, 2019
Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)

August 9, 2019
Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction (pdf)

August 7, 2019
Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference (pdf)

August 6, 2019
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement (pdf)


Events

Canaccord Genuity 39th Annual Growth Conference
Thursday, August 8th, 2019 at 3:00 p.m. Eastern.
Webcast Link: http://wsw.com/webcast/canaccord35/nlt/

Conference call to discuss Neoleukin merger with Aquinox
Tuesday, August 6, 2019 – 9 a.m. Eastern / 6 a.m. Pacific
Webcast Link: https://edge.media-server.com/mmc/p/ktdhvpdd
SLIDE PRESENTATION: Neoleukin Corporate Presentation (PDF)


In The News

Neoleukin emerges with a de novo approach to improving biologics
BioCentury – Emerging Company Profile, July 18 2019

If you build it, they will come: Reaching across the “IL” with Neo-2/15
ScienceImmunology, March 1, 2019

Neoleukin-2/15 – A Novel Immunotherapy Agent Designed to Avoid Common Side Effects
OncoZine, Jan. 16, 2019

Neoleukin Therapeutics Hopes to Improve on Nature's Approach to Battling Cancer
BioSpace, Jan. 11, 2019

Scientists design protein that prods cancer-fighting T-cells
University of Washington Medicine Newsroom, Jan. 10, 2019

New Protein Designed that Mimics IL-2 without Severe Side Effects
Genetic Engineering & Biotechnology News, Jan. 10, 2019

Researchers redesign a cancer-busting protein—without the side effects
Science, Jan. 9, 2019

New Seattle startup emerges from UW to develop cancer-fighting protein three decades in the making
GeekWire, Jan. 9, 2019

MEDIA Contact

contact@neoleukin.com